The effect of FABHALTA on proteinuria and kidney function (estimated glomerular filtration rate, eGFR) was evaluated in a randomized, placebo-controlled, double-blind, multicenter, global study (APPLAUSE-IgAN, NCT04578834) in adults with biopsy-proven primary IgAN, eGFR ≥ 20 mL/min/1.73 m2, and urine protein-to-creatinine ratio (UPCR) ≥1 g/g on a stable dose of maximally-tolerated renin-angiotensin system (RAS) inhibitor therapy with or without a stable dose of a sodium-glucose co-transporter 2 inhibitor (SGLT2i). Patients with other glomerulopathies or those who had been recently treated with systemic immunosuppressants were excluded. Patients were included in either the Main Study Population (eGFR ≥ 30 mL/min/1.73 m2) or the Severe Renal Impairment population (eGFR ≥ 20 and < 30 mL/min/1.73 m2). Within each group, patients were randomized (1:1) to either FABHALTA 200 mg or placebo twice daily. Rescue immunosuppressive treatment could be initiated per investigator discretion during the trial.
Patients were required to be vaccinated against Neisseria meningitidis and Streptococcus pneumoniae and were recommended to be vaccinated against Haemophilus influenzae type b. If the patient had not been previously vaccinated or if a booster was required, vaccination was administered at least 2 weeks prior to first dosing. If FABHALTA treatment was initiated earlier than 2 weeks after vaccination, antibacterial drug prophylaxis was administered.
The primary efficacy endpoint for the interim analysis was the relative change from baseline in UPCR (sampled from a 24-hour urine collection) at Month 9 based on the first 250 randomized patients (Main Study Population). The primary efficacy endpoint for the final analysis was the annualized total eGFR slope over 24 months (Main Study Population).
The 477 patients who enrolled and received study medication had a mean age of 39 years (range 18 to 76 years); 54% were male, 46% White, 52% Asian, and < 1% Black or African American. At baseline, 99% of patients were treated with an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) and 19% were on a SGLT2i. Approximately 59% had a history of hypertension, 5% had a history of type 2 diabetes, and 75% had hematuria based on urine dipstick. At baseline, the mean eGFR was 65 mL/min/1.73 m2, the geometric mean UPCR (sampled from a 24-hour urine collection) was 1.9 g/g, and 25% had proteinuria > 3.5 g/24 hours.
Urine Protein/Creatinine Ratio (UPCR)
The study met the prespecified primary endpoint of relative change from baseline in UPCR (sampled from a 24-hour urine collection) at Month 9 based on an interim analysis of the first 250 randomized patients (Main Study Population) who had completed or discontinued the study prior to the Month 9 visit. The interim analysis showed a 44% decrease in UPCR at Month 9 relative to baseline for patients treated with FABHALTA compared to a 9% decrease for patients treated with placebo resulting in a 38% reduction in the ratio of mean UPCR (95% CI: 26% to 49% reduction; p<0.0001). In the final analysis of 477 randomized patients, the treatment effects on UPCR observed at Month 9 and Month 24 were consistent with the results obtained at the interim analysis.
The geometric mean percent change from baseline in UPCR over the course of the double-blind period is shown in Figure 1.
Figure 1: Geometric Mean Percent Change from Baseline in UPCR [FMV] and 24-hour UPCR by Visit in APPLAUSE-IgAN
Figure 1: Geometric Mean Percent Change From Baseline In Upcr [fmv] And 24-hour Upcr By Visit In Applause-igan (Fabhalta 03)
Log transformed ratio to baseline in UPCR was analyzed using an MMRM with stratification factors: geographic region, baseline eGFR and baseline UPCR. MMRM analysis included UPCR data during the double-blind period up to Month 24 based on all patients. UPCR data after the intercurrent events and missing data were handled by the pre-defined strategies and imputation approaches. 24-hour UPCR and UPCR [FMV] were analyzed separately using the same analysis method. *Represents the number of patients with values non-missing and not imputed as per the intercurrent event handling strategy by visit and treatment group. Abbreviations: bid, twice daily; CI, confidence interval; eGFR, estimated glomerular filtration rate; MMRM, mixed model repeated measures; N, number of patients in each group with non-missing baseline and covariates; UPCR, urine protein-to-creatinine ratio; 24-hour UPCR, urine protein-to-creatinine ratio sampled from a 24-hour urine collection; UPCR [FMV], urine protein-to-creatinine ratio sampled from first morning void.
Estimated Glomerular Filtration Rate (eGFR)
The study met the prespecified primary endpoint for final analysis, the annualized total eGFR slope over 24 months in the Main Study Population. The annualized mean change from baseline in eGFR estimated over a 24-month period was -3.0 mL/min/1.73 m2 per year for FABHALTA and -5.7 mL/min/1.73 m2 per year for placebo, corresponding to a treatment effect of 2.8 mL/min/1.73 m2 per year (95% CI: 1.6, 3.9; p<0.0001). The mean change from baseline in eGFR during the double-blind period is shown in Figure 2.
The treatment effect on the change from baseline in eGFR estimated at 24 months was generally consistent across key subgroups including age, sex, race, baseline disease characteristics (such as baseline eGFR and proteinuria levels), and the use of SGLT2i.
Figure 2: Mean Change from Baseline in eGFR (mL/min/1.73 m2) by Visit in APPLAUSE-IgAN
Figure 2: Mean Change From Baseline In Egfr (ml/min/1.73 M²) By Visit In Applause-igan (Fabhalta 05)
The mean change from baseline in eGFR was estimated from an MMRM with stratification factors: geographic region, baseline eGFR and baseline UPCR. MMRM analysis included all eGFR data during the double-blind period up to Month 24 regardless of treatment discontinuation for any reason with exception of the initiation of kidney replacement therapy which were handled by a worst-case imputation method. * Represents the number of patients with values non-missing and not imputed as per the intercurrent event handling strategy by visit and treatment group. Abbreviations: bid, twice daily; CI, confidence interval; eGFR, estimated glomerular filtration rate; MMRM, mixed model repeated measures; N, number of patients in each group with non-missing baseline and covariates; UPCR, urine protein-to-creatinine ratio.
Table 5 shows the treatment effect of FABHALTA compared to placebo on the key secondary endpoint of time to first occurrence of a kidney composite event, consisting of a sustained ≥30% decline in eGFR from baseline, sustained eGFR <15 mL/min/1.73 m², maintenance dialysis, receipt of kidney transplant, and death from kidney failure. The treatment effect was driven by an effect on a sustained decline in eGFR ≥30% from baseline.
Table 5: Analysis Result for Kidney Composite Endpoint in APPLAUSE-IgANAbbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; n, total number of events included in the analysis; N, number of patients in each group. aAdjusted p-value. bHazard ratio <1 in favor of FABHALTA. Analyzed using Cox proportional hazards model. cFor patients with multiple events, only the first event contributing to the composite endpoint is counted in the table. dOver at least 4 weeks.
In total, 4 patients in the FABHALTA arm and 6 in the placebo arm had sustained eGFR <15 mL/min/1.73 m²; 6 patients in the FABHALTA arm and 4 in the placebo arm required maintenance dialysis; 2 patients in the placebo arm had receipt of kidney transplant; no patients died during the study. |
| Endpoints | FABHALTA (N = 238) n (%) | Placebo (N = 239) n (%) | Difference (95% CI) p-valuea |
| Time to first occurrence of a kidney composite endpointc | 51 (21.4) | 80 (33.5) | Hazard Ratiob 0.6 (0.4, 0.8) p=0.0015 |
| Sustainedd ≥30% decline in eGFR from baseline | 50 (21.0) | 79 (33.1) | |
| Sustainedd eGFR <15 mL/min/1.73 m² | 0 | 0 | |
| Maintenance dialysisd | 1 (0.4) | 1 (0.4) | |
| Receipt of kidney transplant | 0 | 0 | |
| Death from kidney failure | 0 | 0 | |